• Dr Jérôme Doyen

    Radiation Oncologist
    Antoine Lacassagne Cancer Center

Dr Jérôme Doyen is a Radiation Oncologist working at the Centre Antoine-Lacassagne in Nice, France. He’s in charge of the high energy proton activity since 2016 and the arrival of the Proteus One (IBA). The treatment of patients with protons in Nice actually began in 1991 with low energy protons dedicated to the treatment of uveal melanomas. Dr Doyen graduated from the medical school of Nice and he’s particularly involved in the management of brain tumors, sarcomas and lung tumors. He went in Jacksonville, Florida in 2015 in order to prepare the arrival of the new proton activity. Before the development of Proton Therapy he specialized in the treatment of patients with IMRT, VMAT and stereotactic radiotherapy. He’s also involved in fundamental research and works with Gilles Pages in order to compare cytokine production and immune reaction  after Photon and Proton Therapy.

  • Professor Stijn Krol

    Consultant radiation-oncologist Leiden University Medical Center
    Chair, Clinical Team - HollandPTC

Stijn Krol graduated from Leiden University Medical School in 1986, and presently works as a consultant radiation-oncologist in the Leiden University Medical Center (LUMC) and affiliated hospitals. His main interests are treatment of patients with lymphomas, sarcomas and prostate carcinomas. He defended his thesis on extranodal Non-Hodgkin’s lymphomas in 2002 and at present late effects of radiotherapy is his main area of scientific interest. In recent years he is member of the project team HollandPTC, a collaboration between ErasmusMC Rotterdam, the Delft University of Technology and LUMC, aiming at the introduction of proton therapy in the Netherlands in 2017

  • Professor Oliver Jäkel

    Medical Physics Director, HIT GmbH

Prof. Oliver Jäkel studied Physics at the University Erlangen, where he also obtained his PhD in theoretical particle physics in 1994.
Since 2005 he has been part of the team preparing for the clinical startup of the Heidelberg Ion Beam Therapy Facility HIT at the University hospital Heidelberg..
In 2010 he was appointed a full professorship for Medical Physics at the Medical Faculty of Heidelberg University, and is now chair and head of the department for Medical Physics in Radiation Oncology at the German Cancer Research Center DKFZ.

  • Justin Bekelman

    Associate Professor of Radiation Oncology
    Hospital of the University of Pennsylvania

Justin E. Bekelman, M.D., is Associate Professor in the Department of Radiation Oncology (Primary) and the Department of Medical Ethics and Health Policy (Secondary) at the Perelman School of Medicine, Associate Scholar in the Center for Clinical Epidemiology and Biostatistics, Faculty in the Center for Health Incentives and Behavioral Economics, and Senior Fellow at the Leonard Davis Institute for Health Economics at the University of Pennsylvania. Dr. Bekelman leads research programs in cancer comparative effectiveness and delivery system and payment reform, integrating methods from the fields of epidemiology, clinical trials, health economics and public policy. In his current comparative effectiveness work, Dr. Bekelman leads the multi-institution Radiation Comparative Effectiveness Consortium (RADCOMP) pragmatic randomized clinical trial comparing proton to photon radiation therapy for breast cancer (the largest randomized trial of proton and photon delivery in the modern treatment era) and co -leads the PARTIQoL randomized clinical trial comparing proton to intensity-modulated radiation therapy (IMRT) for prostate cancer. In his delivery system and payment reform work, Dr. Bekelman leads a series of quasi-experimental studies to evaluate the impact of narrow networks and reimbursement reforms on the use, costs, quality and outcomes of cancer treatments.

  • Professor Dirk De Ruysscher

    Radiation Oncologist, Maastro Clinic
    Maastricht University Medical Center

Dr. De Ruysscher earned his medical degree at the University of Leuven, Belgium, in 1986, and became a radiation oncologist at the same university in 1991. In 1992, he obtained his PhD thesis from the University of Leuven on the influence of radiotherapy on immunity.

Prof. Dirk De Ruysscher specialises in lung cancer and pioneered the integration of molecular imaging in radiation treatment planning and individualised radiotherapy schedules.

Prof. De Ruysscher is a full Professor of Respiratory Oncology at the Maastricht University Medical Center, Maastricht, the Netherlands, and a full Professor of Radiation Oncology at the University of Leuven, Belgium, and has been a visiting Professor at the Massachusetts General Hospital and the Francis H. Burr Proton Therapy Center, Boston, MA, USA, the Departments of Human Oncology and Medical Physics, University of Wisconsin at Madison, USA and The Christie, Manchester University, Manchester, United Kingdom.

  • Professor Andrey Solov’yov

    Scientific and Executive Director
    MBN Research Center at FiZ

Professor Andrey V. Solov’yov was graduated from St. Petersburg State Polytechnical University, got Ph.D. in theoretical and mathematical physics at the A.F. Ioffe Physical-Technical Institute of the Russian Academy of Sciences. Currently, he is Director of MBN Research Center in Frankfurt am Main, Germany; Professor of Theoretical Physics; Visiting Professor at the Open University, Milton Keynes, UK; President of VINF (Virtual Institute of Nano Films); Coordinator of the HORIZON2020 RISE-PEARL Project; Editor in Chief, European Physical Journal D: Atomic Molecular, Optical and Plasma Physics; recipient of numerous scientific awards

  • Professor Tadashi Kamada

    NIRS Research Center for Charged Particle Therapy

Professor Kamada graduated from Hokkaido University School of Medicine in 1979 and is currently the director at the Research Centre for Charged Particle Therapy, Independent Administrative Agency National Institute of Radiological Sciences, which is the pioneer of Japanese heavy ion radiotherapy facilities, having treated around 6,500 patients. He is also a visiting professor at Chiba University Graduate School of Medicine. His special fields of interest include radiation oncology, and bone and soft tissue tumours.

  • Dr Jiří Kubeš

    Medical Director
    Proton Therapy Centre Czech

Jiří has obtained a great deal of clinical experience in leading positions as a radiation oncologist at several institutions. He is a vice-chairman of the Czech Society for radiation oncology, biology and physics. Besides being an active lecturer, he specializes in prostate carcinoma as well as head and neck tumours. He is now Medical Director of Proton Therapy Centre Czech in Prague.

  • Dr Vladimír Vondráček

    Head of Clinical Physics
    Proton Therapy Centre Czech

MSc. Vladimír Vondráček is Head of Clinical Physics. He gained a great deal of experience in medical physics and nuclear safety at several institutions. He actively cooperates in the training of medical physicists and in the preparation of international nuclear research projects. He has a great appreciation for the advanced technology of proton therapy.

  • Professor Damien Weber

    Head and Chairman

Professor Damien Weber undertook his postdoctoral training at the University Hospital of Geneva and went on to become Vice Chair of the universities radiation oncology department. He is now Head and Chairman at The Centre for Proton Therapy, The Paul Scherrer Institute. PSI is the largest research center for natural and engineering sciences within Switzerland. By conducting fundamental and applied research, PSI works on long-term solutions for major challenges facing society, industry and science. Professor Weber has (co-)authored over 90 papers, reviews and book chapters.

  • Dr Jem Rashbass

    Director for National Disease Registration
    Public Health England

Jem Rashbass studied medicine at University College London was a graduate student of Professor Sir John Gurdon in Cambridge, then trained in diagnostic pathology, becoming a clinical academic dividing his time between clinical work and the creation of Clinical and Biomedical Computing Unit at Cambridge University.
In 2003 he became head of the Eastern Cancer Registry and Information Centre, a post he held in conjunction with the leadership of the East of England Cancer Screening Quality Assurance Service. In April 2013 was appointed National Director for Disease Registration in PHE responsible for the 300 staff in National Disease Registration; in January 2016 he also combined the oversight of the cancer analysis functions to create the new National Cancer Registration and Analysis Service for England.

  • Dr Håkan Nyström

    Chief Physicist, Head of Clinic
    Skandion, Uppsala

Dr Håkan Nyström was born in 1958 in the far north of Sweden. He received his PhD in radiation physics at Umeå University. From 1998 – 2007 he was the head of medical physics at the radiotherapy clinic of Rigshospitalet, Copenhagen, Denmark. In 2007 he took his current position working for the Skandion Clinic, Uppsala, Sweden and is now head of clinic.

  • Professor Stephanie Combs

    Director of the Clinic for Radiation Oncology and Radiation
    Technical University of Munich

Stephanie E. Combs is Professor and Chair of the Department of Radiation Oncology at the Technical University of Munich (TUM), Munich, Germany, since 2014. Before, she was Vice Chair of the Department of Radiation Oncology in Heidelberg, Germany.
She also holds the position as Director of the Institute of Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), at the Helmholtz Zentrum München (HMGU). Prof. Combs is Chair of the Oncological Center (Onkologisches Zentrum) at TUM, and Vice Chair of the Tumor Center Munich (Tumozentrum München, TZM).
She was trained as a radiation oncologist in Heidelberg, where she specialized in high-precision radiotherapy such as radiosurgery, stereotactic treatments, Intensity Modulated Radiotherapy (IMRT) as well as particle therapy. Her special interest is treatment individualization and optimization of patients with brain tumors and tumors of the skull base, gastrointestinal malignancies as well as childhood cancer. She has set up and conducted over 20 clinical trials, and published over 175 original peer-reviewed articles. Prof. Combs is a member of the German and European Radiation Oncology Societies (DEGRO and ESTRO), the American Society of Radiation Oncology (ASTRO). She is serving as a board member of the Neurooncological Working Group of the German Cancer Society (DKG). She received several scientific awards for her work such as the Hermann Holthusen Prize of the German Radiation Oncology Society.

  • Professor Beate Timmermann

    Director of the Clinic for Particle Therapy, University Hospital Essen and Medical Director of the West German Proton Therapy Centre, Essen
    The West German Proton Therapy Centre, Essen

Prof. Dr. Beate Timmermann is Director of the Clinic for Particle Therapy, University Hospital Essen, and Medical Director of the West German Proton Therapy Centre, Essen. She is one of the worldwide leading specialists in the area of radiotherapy and radio-oncology, especially in the area of proton therapy. A special focus of the West German Proton Therapy Centre is the treatment of children. At the West German Proton Therapy Centre, even the irradiation of children younger than five years is possible. Because their tissue is still developing, children are still particularly vulnerable to the side effects of irradiation. However, thanks to the highly controllable nature of radiation therapy with protons, normal tissue is largely protected. With protons, it is therefore possible to reduce the risk of negative consequences and secondary tumours. Since 2002, Dr Timmermann has dealt with establishing proton therapy for children.

  • Jorn Verweij

    Project Leader Proton Therapy
    Trees with Character

Jorn Verweij has been trained as a medical physicist and has 15+ years experience in proton
therapy, from treating 1800+ patients at the Paul Scherrer Institute to project managing a proton
therapy center in Amsterdam, The Netherlands. In this last role he was responsible for the
selection of a proton therapy vendor. The procurement methodology used did not involve the
listing of requirements, and did not include exchanges of detailed technical information. It was
successfully run and, when it was legally challenged, the court ruled in favour of the project on
all accounts and so paved the path for others.

  • Professor Yolande Lievens

    Professor of Radiation Oncology
    University of Ghent

Yolande was Professor in Radiation Oncology at the University of Leuven from 2002 and took up her current appointment as Professor at the University of Ghent in October 2012. She takes an active part in educational activities in Belgium and internationally. Yolande’s clinical interests in pulmonary oncology, haematology and breast cancer are reflected in her research projects, which largely take place within the interdisciplinary oncology groups of the hospitals where she works and through EORTC collaborations. Besides her clinical research, Yolande has a keen interest in the economic aspects of radiotherapy and oncology. She has collaborated in numerous projects with various groups and organisations, such as ESTRO, the International Atomic Energy Agency, the Belgian Hadron Therapy Center Foundation and the Belgian Health Care Knowledge Centre.

  • Professor Johannes Langendijk

    Chair of Department of Radiation Oncology
    University of Groningen

Professor Hans Langendijk graduated from the Vrije University in Amsterdam School of Medicine in 1989. His special interests are head and neck oncology, prediction and prevention of radiation-induced side effects and proton therapy. In addition, he has a major interest in developing new methodologies to validate new radiation technologies.

He is (co-)author of more than 260 peer reviewed scientific papers and book chapters in particular on head and neck cancer and radiation-induced side effects.

  • Professor Michael Brada

    Professor of Radiation Oncology
    University of Liverpool

Michael is a Professor of Radiation Oncology at the University of Liverpool; previously Professor of Clinical Oncology at ICR and the Royal Marsden Hospital, London. He is a leading international expert in neuro-oncology and thoracic oncology. He is also involved in evaluation of technologies through systematic reviews and meta-analyses, which have not infrequently generated heated debates. He has authored and co-authored more than 250 peer-reviewed articles, editorials, and book chapters and countless abstracts and invited lectures at national and international conferences and meetings.

  • Professor Philippe Lambin

    Director, Maastricht Radiation Oncology Clinic
    University of Maastricht and MAASTRO Clinic

Prof. Philippe Lambin is a clinician, Radiation Oncologist, pioneer in translational research with a focus on hypoxia, imaging and Decision Support Systems. He has a PhD in Radiation Biology and is professor at the University of Maastricht (Radiation Oncology). He is co-author of more than 355 peer reviewed scientific papers and co-inventor of more than 15 patents. His main areas of interest are directed towards translational research in Radiation Biology with a specific focus on tumour hypoxia, functional imaging (CT-PET), lung and head and neck cancer. He has a recent interest in the development of multifactorial ‘treatment decision support system’ (www.predictcancer.org). He has been a visiting professor at the University of Leuven, Philadelphia and Toronto.

  • Professor Gillies McKenna

    Director of Oxford Institute for Radiation Oncology
    University of Oxford

Professor Gillies McKenna is the director of the Oxford Institute for Radiation Oncology and head of the Department of Oncology at the University of Oxford. Dr. McKenna’s research links basic science studies with translational-clinical applications and is focused on understanding effects of radiotherapy on cells and how cancers can become resistant to it. Dr. McKenna is the author of more than 90 research articles and 40 editorials, reviews, and chapters. He is past president of the Radiation Research Society and a member of the Board of Scientific Advisors for the National Cancer Institute.

  • Professor Petra Witt Nyström

    Specialist Physician, Experimental and Clinical Oncology
    Uppsala University

Petra Witt Nyström graduated in 1991 from the University of Gothenburg, Sweden
In 2009 she received her PhD from the University of Aarhus, Denmark. Thesis: “Marine poly-unsaturated fatty acids and breast cancer”
She is currently Consultant at the Department of Oncology, Uppsala University Hospital, Sweden and at the Skandion Clinic, Uppsala, Sweden Her Special areas of interest and research fields include Cardiotoxicity in breast cancer radiotherapy, Neuro-oncology, Proton therapy of CNS tumours and in the treatment of breast cancer.